Related trials
PACES (Simonneau), 2008 - Sildenafil vs Placebo
EARLY (Galie), 2008 - Bosentan vs Placebo
ARIES (Galie=, 2008 - Ambrisentan vs Placebo
COMBI (Hoeper), 2006 - Inhaled iloprost vs Placebo
Singh, 2006 - Sildenafil vs Placebo
STEP (McLaughlin), 2006 - Inhaled iloprost vs Placebo
STRIDE-2 (Barst), 2006 - Sitaxsentan vs Placebo
BREATH-5 (Galie), 2006 - Bosentan vs Placebo
SERAPH (Wilkins), 2005 - Bosentan vs Sildenafil
SUPER-1 (Galie), 2005 - Sildenafil vs Placebo
STRIDE-1 (Barst), 2004 - Sitaxsentan vs Placebo
BREATH-2 (Humbert), 2004 - Epoprostenol + Bosentan vs Epoprostenol + placebo
Sastry, 2004 - Sildenafil vs Placebo
Barst, 2003 - Beraprost vs Placebo
BREATHE-1 (Rubin), 2002 - Bosentan vs Placebo
Langleben, 2002 - Terbogrel vs Placebo
AIR (Olschewski), 2002 - Iloprost vs Placebo
ALPHABET (Galie), 2002 - Beraprost vs Placebo
Simmoneau, 2002 - Treprostinil vs Placebo
Channick, 2001 - Bosentan vs Placebo
Badesch, 2000 - Epoprostenol vs control
Barst, 1996 - Epoprostenol vs control
Rubin, 1990 - Epoprostenol vs control
See also:
All pulmonary hypertension clinical trials
All clinical trials of All mecanism
All clinical trials of Beraprost
|
|
Treatments
Studied treatment |
Beraprost
|
Control treatment |
Placebo
|
Patients
Method and design
Randomized effectives |
60 / 56 (studied vs. control) |
Follow-up duration |
36 weeks |
Primary endpoint |
VO2 max |
Results
Endpoint
Studied treat. n/N
Control treat. n/N
Graph
RR [95% CI]
All cause death
1 / 60
2 / 56
classic
0,47 [0,04;5,01]
0
2
1.0
Relative risks
|
Endpoint |
Events (%) |
Relative Risk |
95% CI |
Endpoint definition in the trial |
Ref |
Studied treat. |
Control treat. |
All cause death
|
1 / 60 (1,7%) |
2 / 56 (3,6%) |
0,47 |
[0,04;5,01] |
|
10044 |
The primary endpoint (if exists) appears in blod characters
|
Reference(s) used for data extraction:
10044: Gali� N, Manes A, Negro L, Palazzini M, Bacchi Reggiani ML, Branzi AEur Heart J 2009;:
|
Endpoint |
studied treat. |
control treat. |
mean diff |
Absolute risk reduction
|
Endpoint |
Events rate |
Absolute risk reduction (ARR) |
Studied treat. |
Control treat. |
All cause death |
1,67% |
3,57% |
-19,0‰
|
Meta-analysis of all similar trials:
All mecanism in pulmonary hypertension for all patients
Reference(s)
-
Barst RJ, McGoon M, Mc Laughlin VV, Tapson V, Rich S, Rubin L, Wasserman K,.
.
J Am Coll Cardiol 2003;41:2125
Pubmed
|
Hubmed
| Fulltext
|